The report provides comprehensive information on the
therapeutics under development for Botulism, complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview
of key players involved in therapeutic development for Botulism and features
dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619246-botulism-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
-The report provides a snapshot of the global therapeutic
landscape of Botulism
- The report reviews pipeline therapeutics for Botulism by
companies and universities/research institutes based on information derived
from company and industry-specific sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Botulism
therapeutics and enlists all their major and minor projects
- The report assesses Botulism therapeutics based on drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Botulism
Reasons to
buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Botulism
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Botulism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Botulism Overview 7
Therapeutics Development 8
Pipeline Products for Botulism - Overview 8
Pipeline Products for Botulism - Comparative Analysis 9
Botulism - Therapeutics under Development by Companies 10
Botulism - Therapeutics under Investigation by
Universities/Institutes 11
Botulism - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Botulism - Products under Development by Companies 14
Botulism - Products under Investigation by
Universities/Institutes 15
Botulism - Companies Involved in Therapeutics Development 16
CytoDel, LLC 16
Hawaii Biotech, Inc. 17
Microbiotix, Inc. 18
Molecular Targeting Technologies, Inc. 19
Nanotherapeutics, Inc. 20
Planet Biotechnology Inc. 21
XOMA Corporation 22
Botulism - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
BoNT/A HcR4 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
botulinum vaccine - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
botulism [serotype C] vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
botulism [serotypes A, B, C, D, E] vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
botulism [serotypes A, B] vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Ctyo-111 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism
- Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
OSX-400 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
OSX-400 Backups - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Polyclonal Antibody for Botulism - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Recombinant Peptides to Inhibit Botulinum Toxin for Botulism
- Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment